Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating ...
Sera (SERA) market outlook \| revenue expansion trends, trading activity, investor sentiment. Sera Prognostics Inc. (SERA) ...
Sera Prognostics, Inc. (SERA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy ...
The company targets active discussions in 15–17 states and aims to run 5–7 partner programs by the end of 2026, representing 58–60% of U.S. births. Aerts explained, "We have budgeted the same -- ...
SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by ...
SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy ...
"Following the results of our full PRIME pivotal study being publicized we are leveraging them by engaging with key plan providers in focused geographic regions hard hit by premature birth," said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results